ArticleGynecologic oncology reports2026
Intraperitoneal OK-432 infusion for postoperative lymphatic leakage in gynecologic tumors.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative lymphatic leakage is a challenging complication following radical surgery for gynecologic malignancies. Effective medical treatment for controlling lymphatic leakage is still lacking. This study analyzed the clinical efficacy and safety of intraperitoneal OK-432 perfusion for managing postoperative lymphatic leakage. Methods: We conducted a retrospective cohort study involving 9 patients who developed postoperative lymphatic leakage after pelvic lymph node dissection with or without para-aortic lymphadenectomy for gynecologic tumors. All patients received a single intraperitoneal perfusion of OK-432. Results: The mean age and BMI of the patients were 53.1 years old and 22.7. The primary site was endometrium, ovary, cervix and fallopian tube in 5, 1, 2, and 1 patient, respectively. Most patients had adenocarcinoma (6/9). The FIGO stages were I, II, and III in 3 patients each. The mean number of resected lymph nodes was 24.6 and 7 patients underwent para-aortic lymphadenectomy. Seven patients underwent robotic/laparoscopic surgery while open surgery was applied in 2 patients. In terms of efficacy, the median time to drainage tube removal was 4 days. Although pretreatment drainage volume was high, post-treatment drainage volume decreased remarkably. With a median follow-up of 2.7 years and 100% follow-up rate, no chronic pelvic pain, lower-limb lymphedema, persistent lymphoceles, or tumor recurrences were observed. Conclusion: Intraperitoneal OK-432 perfusion is a safe and effective treatment for postoperative lymphatic leakage following gynecologic tumor surgery. It may shorten drainage duration, avoids reoperation, and may offer a therapeutic alternative to current treatments for postoperative lymphatic leakage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.